Viral infection after renal transplantation: Surveillance and management

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue SUPPL. 2, 2008, Pages

  Weikert, Blair C ^a   Blumberg, Emily A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

HUMAN; KIDNEY TRANSPLANTATION; MORTALITY; POSTOPERATIVE COMPLICATION; REVIEW; VIROLOGY; VIRUS INFECTION;

ANTIVIRAL AGENTS; HUMANS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; VIRUS DISEASES;

EID: 41749089403     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02900707     Document Type: Review

References (105)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4: 378, 2004
2. Patel R, Paya C: Infections in solid-organ transplant patients. Clin Microbiol Rev 10: 86-124, 1997
3. Hartmann A, Sagedal S, Hjelmesaeth J: The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation 82[Suppl]: S15-S17, 2006
4. Toyoda M, Puliyanda D, Amet N, Baden L, Cam V, Radha R, Pao A, Vo A, Bunnapradist S, Moudgil A, Jordan S: Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients. Transplantation 80: 198-205, 2005
5. Boubenider S, Hiesse C, Marchand S, Hafi A, Kriaa F, Charpentier B: Post transplant polyomavirus infections. J Nephrol 12: 24-29, 1999
6. Sageda S, Nordal KP, Hartmann A, Sund S, Scott H, Degré M, Foss A, Leivestad T, Osnes K, Fauchald P, Rollag H: The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2: 850-856, 2002
7. Brennan DC: Cytomegalovirus in renal transplantation. J Am Soc Nephrol 12: 848-855, 2001
8. Zhang LG, Hanpf P, Rutherford C: Churchill WH, Crumpacker CS. Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. J Infect Dis 171: 1002-1006, 1995
9. Crumpacker CS, Wadhwa S. Cytomegalovirus. In: Principles and Practices of Infectious Diseases, 4th Ed., edited by Mandell GM, Bennett JE, Dolin R, New York, Churchill Livingstone, 2005, pp 1786-1801
10. Green M, Avery R, Preiksaitis J. Guidelines for the prevention and management of infectious complications of solid organ transplantation. Am J Transplant 4[Suppl 10]: 10-17, 57-109, 160-163, 2004
11. Liapis H, Storch G, Hill DA, Rueda J, Brennan D: CMV infection of the renal allograft is much more common than the pathology indicates: A retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue CMV-PCR. Nephrol Dial Transplant 18: 397-402, 2003
12. Birk PE, Chavers BM: Does cytomegalovirus cause glomerular injury in renal allograft recipients? J Am Soc Nephrol 8: 1801-1808, 1997
13. Falagas ME, Snydman DR, Griffith J, Werner BG, Freeman R, Rohrer R: Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study group. Clin Infect Dis 25: 314-317, 1997
14. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M: Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356: 645-649, 2000
15. Schnitzler MA, Woodward RS, Brennan DC, Spitznagel E, Dunagan WC, Bailey TC: The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: Implications for organ allocation. Am J Kidney Dis 29: 428-434, 1997
16. Nosari A, Montillo M, Morra E: Infectious toxicity using alemtuzumab. Haematologica 89: 1415-1419, 2004
17. Moreso F, Seron D, Morales JM, Cruzado JM, Gil-Vernet S, Pérez JL, Fulladosa X, Andrés A, Grinyó JM: Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant 12: 198-205, 1998
18. Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudrealault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC: Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6: 2134-2143, 2006
19. Small LN, Lau J, Snydman DR: Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 43: 869-880, 2006
20. Puius YA, Snydman DR: Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: Current approach and future challenges. Curr Opin Infect Dis 20: 419-424, 2007
21. Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, Vimalachandra D, Craig JC: Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomized controlled trials. Lancet 365: 2105-2115, 2005
22. Paya CV, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD, Valganciclovir Solid Organ Transplant Study Group: Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in sold organ transplant recipients. Am J Transplant 4: 611-620, 2004
23. Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C, Pescovitz M, Humar A, Dominiguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Covington E: Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 189: 1615-1618, 2004
24. Preiksaitis JK, Pang X-L, Fox JD, Fenton J, Miller G, Caliendo A: Inter-laboratory comparison of cytomegalovirus (CMV) viral load (VL) assays [Abstract 196]. Am J Transplant 7[Suppl 2]: 197, 2007
25. Martin DF, Sierra-Madero J, Walmsley S, Wolitz R, Macey K, Georgiou P, Robinson C, Stempien MJ, Valganciclovir Study Group: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 346: 1119-1126, 2002 [published erratum appears in N Engl J Med 347: 862, 2002]
26. Babel N, Gabdrakhmanova L, Juergensen JS, Eibl N, Hoerstrup J, Hammer M, Rosenberger C, Hoeflich C, Frei U, Rohde F, Volk HD, Reinke P: Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: A single center experience. Transplantation 78: 283-285, 2004
27. Asberg A, Humar A, Rollag H, Jardine AG, Mouas M, Pescovitz D, Sgarabotto D, Tuncer M, Noronha IL, Hartmann A: Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 7: 2106-2113, 2007
28. Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush HL, Levey AS, et al.: Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317: 1049-1054, 1987
29. Drew WL, Paya CV, Emery V: Cytomegalovirus (CMV) resistance to antivirals. Am J Transplant 1: 307-312, 2001
30. John GT, Manivannan J, Chandry S, Peter S, Jacob CK: Leflunomide therapy for cytomegalovirus disease in renal allograft recipients. Transplantation 77: 1460-1461, 2004
31. John GT, Manivannan J, Chandy S, Peter S, Fleming DH, Chandy SJ, Balakrishnan N, Krisnamurthy K, Kirubakaran MG, Jacob CK: A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant Proc 37: 4303-4305, 2005
32. Cowan FM, Copas A, Johnson AM, Ashley R, Corey L, Mindel A: Herpes simplex type 1 infection: A sexually transmitted infection of adolescence? Sex Transm Infect 78: 346-348, 2002
33. Fehr T, Bossart W, Wahl C, Binswanger U: Disseminated varicella infection in adult renal allograft recipients: Four cases and a review of the literature. Transplantation 73: 608-611, 2002
34. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL; Shingles Prevention Study Group: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352: 2271-2284, 2005
35. Kotton CN, Fishman JA: Viral infection in the renal transplant recipient. J Am Soc Nephrol 16: 1758-1774, 2005
36. Tan HH, Goh CL: Viral infections affecting the skin in organ transplant recipients: Epidemiology and current management strategies. Am J Clin Dermatol 7: 13-29, 2006
37. Hanto DW: Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: Implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 46: 381-394, 1995
38. Opelz G, Naujokat C, Daniel V, Terness P, Dohler B: Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 81: 1227-1233, 2006
39. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA: Posttransplant lymphoproliferative disorder in renal allograft recipients: Clinical experience and risk factor analysis in a single center. Transplantation 56: 88-96, 1993
40. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD: Ganciclovir and acyclovir reduce the risk of posttransplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 5: 2894-2900, 2005
41. Green M, Michaels MG, Katz BZ, Burroughs M, Gerber D, Shneider BL, Newell K, Rowe D, Reyes J: CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 6: 1906-1912, 2006
42. Nalesnik MA: The diverse pathology of post-transplant lymphoproliferative disorders: The importance of a standardized approach. Transpl Infect Dis 3: 88-96, 2001
43. Tsai D, Hardy C, Tomaszewski J, Kotloff R, Oltoff K, Somer B, Schuster S, Porter D, Montone K, Stadtmauer E: Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Follow-up of 42 adult patients. Transplantation 71: 1076-1088, 2001
44. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P, Hurault de Ligny B, Dubief F, Mathieu-Boue A, Leblond V: Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 11[Suppl 1]: 113-116, 2000
45. Pescovitz MD: Rituximab, an anti CD20 monoclonal antibody: History and mechanism of action. Am J Transplant 6: 859-866, 2006
46. Johnson SR, Cherikh WS, Kauffman HM, Pavlakis M, Hanto DW: Retransplantation after post-transplant lymphoproliferative disorders: An OPTN/UNOS database analysis. Am J Transplant 6: 2743-2749, 2006
47. Trofe J, Buell JF, Beebe TM, Hanaway MJ, First MR, Alloway RR, Gross TG, Succop P, Woodle ES: Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: The Israel Penn International Transplant Tumor Registry experience. Am J Transplant 5: 775-780, 2005
48. Singh N, Carrigan D: Human herpesvirus-6 in transplantation: An emerging pathogen. Ann Intern Med 124: 1065-1071, 1996
49. Deborska D, Durlik M, Sadowska A, Nowacka-Cieciura E, Pazik J, Lewendowski Z, Chmura A, Galazka Z, Paczek L, Lao M: Human herpesvirus-6 in renal transplant recipients: Potential risk factors for the development of human herpesvirus-6 seroconversion. Transplant Proc 35: 2199-2201, 2003
50. DesJardin JA, Gibbons L, Cho E, Supran SE, Falagas ME, Werner BG, Snydman DR: Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J Infect Dis 178: 1783-1786, 1998
51. Kidd MI, Clark DA, Sabin CA, Andrew D, Hassan-Walker AF, Sweny P, Griffiths PD, Emery VC: Prospective study of human betaherpesviruses after renal transplantation: Association of human herpesvirus 7 and cytomegalovirus coinfection with cytomegalovirus disease and increased rejection. Transplantation 69: 2400-2404, 2000
52. Tong CY, Bakran A, Peiris JS, Muir P, Herrington CS: The association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation. Transplantation 74: 576-578, 2002
53. Diociaiuti A, Nanni G, Cattani P, Lesnoni La Parola I, Masini, Capuano M, Pozzetto U, Fadda G, Castagneto M, Cerimele D: HHV 8 in renal transplant recipients. Transpl Int 13[Suppl 1]: S410-S412, 2000
54. Regamy N, Tamm M, Wernli M, Witschi A, Thiel G, Cathomas G, Erb P: Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 339: 1358-1363, 1998
55. Qunibi W, Akhtar M, Sheth K, Ginn HE, Al-Furayh O, DeVol EB, Taher S: Kaposi's sarcoma: The most common tumor after renal transplantation in Saudi Arabia. Am J Med 84: 225-232, 1988
56. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesuldo L, Schena FP, Grandaliano G: Sirolimus for Kaposi's sarcoma in renal transplant recipients. N Engl J Med 352: 1317-1323, 2005
57. Zmonarski SC, Boratynska M, Rabczynski J, Kazimierczak K, Klinger M: Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 37: 964-966, 2005
58. Luppi M, Barozzi P, Rasini V, Riva G, Re A, Rossi G, Setti G, Sandrini S, Facchetti F, Torelli G: Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. Transplantation 74: 131-133, 2002
59. Demeter LM: JC, BK, and other polyomaviruses: Progressive multifocal leukoencephalopathy. In: Principles and Practices of Infectious Diseases, 4th ed., edited by Mandell GM, Bennett JE, Dolin R, New York, Churchill Livingstone, 2005, pp 1856-1863
60. Mylonakis E, Goes N, Rubin RH, Cosimi AB, Colvin RB, Fishman JA: BK virus in solid organ transplant recipients: An emerging syndrome. Transplantation 72: 1587-1592, 2001
61. Chesters PM, Heritage J, McCance DJ: Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis 147: 676-684, 1983
62. Randhawa PS, Finkelstein S, Scantelbury V, Shapiro R, Vivas C, Jordan M, Picken MM, Demetris AJ: Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 67: 103-109, 1999
63. Hirsch H, Brennan D, Drachenberg C, Ginevri F, Gordon J, Limaye AP, Mihatsch M, Nickeleit V, Ramos E, Randhawa P, Shapiro R, Steiger J, Suthanthiran M, Trofe J: Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 79: 1277-1286, 2005
64. Trofe J, Gaber LW, Stratta RJ, Shokouh-Amin MH, Vera SR, Alloway RR, Lo A, Gaber AO, Eqidi MF: Polyomavirus in kidney and kidney-pancreas transplant recipients. Transplant Infect Dis 5: 21-28, 2003
65. Randhawa P, Brennan DC: BK virus in transplant recipients: An overview and update. Am J Transplant 6: 2000-2005, 2006
66. Phillips T, Jacobs R, Ellis EN: Polyoma nephropathy and progressive multifocal leukoencephalopathy in a renal transplant recipient. J Child Neurol 19: 301-304, 2004
67. Kazoury A, Ducloux D, Chalopin JM, Angonin R, Fontaniere B, Moret H: The first case of JC virus allograft nephropathy. Transplantation 76: 1653-1655, 2003
68. Randhawa P, Baksh F, Aoki N, Tschirhart D, Finkelstein S: JC virus infection in allograft kidneys: Analysis by polymerase chain reaction and immunohistochemistry. Transplantation 71: 1300-1303, 2001
69. Josephson MA, Williams JW, Chandraker A, Randhawa PS: Polyomavirus-associated nephropathy: Update on antiviral strategies. Transplant Infect Dis 8: 95-101, 2006
70. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 50: 1-43, 2001
71. Mat O, Mestrez F, Beauwens R, Muniz-Martiniez MC, Dhaene M: Primary high-dose intradermal hepatitis B vaccination in hemodialysis: Cost effectiveness evaluation at 2 years. Hemodial Int 10: 49-55, 2006
72. Chow KM, Law MC, Leung CB, Szeto CC, Li PK: Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract 103: 89-93, 2006
73. Fornairon S, Pol S, Legendre C, Carnot F, Mamzer-Bruneel MF, Brechot C, Kreis H: The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 62: 297-299, 1996
74. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel CF, Bernard B, Opolon P, Coriat P, Bitker MO: Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29: 257-263, 1999
75. Fabrizi F, Martin P, Ponticelli C: Hepatitis B virus and renal transplantation. Nephron 90: 241-251, 2002
76. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C: Efficacy of long-term lamivudine monotherapy in patients with Hep B e antigen negative chronic hepatitis B. Hepatology 32: 847-851, 2003
77. Fabrizi F, Lunghi G, Poordad FF, Martin P: Management of hepatitis B after renal transplantation: an update. J Nephrol 15: 113-122, 2002
78. Veroux M, Puliatti C, Macarone M, Capello D, Gagliano M, Spataro M, DiMare M, Giuffrida G, Veroux P: Kidney transplantation from hepatitis B surface antigen-positive donors into hepatitis B surface antigen-positive recipients: Preliminary findings. Transplant Proc 37: 2467-2468, 2005
79. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, Melzer JS, Roberts JP, Tomlanovich SJ, Vincenti F, Stock P: The risk of transmision of hepatitis B from Hpb-sag(-), Hbcab(+), Hbigm(-) organ donors. Transplantaion 59: 230-234, 1995
80. Fong TL, Bunnapradist S, Jordan SC, Cho YW: Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: Analysis of United Network of Organ Sharing database between 1994 and 1999. Transplantation 73: 85-89, 2002
81. Chung RT, Feng S, Delmonico FL: Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 1: 185-191, 2001
82. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA: The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 4: 2032-2037, 2004
83. Casanovas TT, Baliellas C, Sese E, Iborra MJ, Benasco C, Andres E, Gonzalez MT, Gil-Vernet S, Casanova A, Casais LA: Interferon may be useful in hemodialysis patients with hepatitis C virus chronic infection who are candidates for renal transplant. Transplant Proc 27: 2229-2230, 1995
84. Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano T, Cassanova A, Perez J, Guerrero L, Gonzalez T, Andres E, Gil-Vernet S, Casais LA: Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: Results after transplantation. Am J Gastroenterol 96: 1170-1177, 2001
85. Kramer P, ten Kate F, Bijnen A, Jeekel J, Weimar W: The pathology of interferon-induced allograft lesions. Transplant Proc 17: 58-60, 1985
86. Shu KH, Lan JL, Wu MJ, Cheng CH, Chen CH, Lee WC, Chang HR, Lian JD: Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 77: 1894-1896, 2004
87. Kamar N, Sandres-Saune K, Selves J, Ribes D: Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: Effects on renal function and liver histology. Am J Kidney Dis 42: 184-192, 2003
88. Kamar N, Boulestin A, Selves J, Esposito L, Sandres-Saune K, Stebenet M, Chatelut E, Durand D, Rostaing L, Izopet J: Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C. J Med Virol 76: 61-68, 2005
89. Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N: Chronic hepatitis C virus infection in renal transplant: Treatment and outcome. Clin Transplant 20: 677-683, 2006
90. Fontaine H, Vallet-Pichard A, Equi-Andrade C, Nalpas B, Verkarre V, Chaix ML, Lebray P, Sobesky R, Serpaggi J, Kreis H, Pol S: Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 78: 853-857, 2004
91. Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, Terrault NA, Frassetto LA, Palefsky JM, Tomlanovich SJ, Ascher NL: Kidney and liver transplantation in human immunodeficiency virus-infected patients: A pilot safety and efficacy study. Transplantation 76: 370-375, 2003
92. Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL: Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 15: 1633-1639, 2004
93. Qiu J, Terasaki PI, Waki K, Cai J, Gjertson DW: HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation 81: 1658-1661, 2006
94. Kumar MSA, Sierka DR, Damask AM, Fyfe B, Mcalack RF, Heifets M, Moritz MJ, Alvarez D, Kumar A: Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 67: 1622-1629, 2005
95. Carter JT, Melcher ML, Carlson LL, Roland ME, Stock PG: Thymoglobulin-associated CD4+ T-Cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant 6: 753-760, 2006
96. Pham TT, Burchette JR Jr, Hale LP: Fatal disseminated adenovirus infections in immunocompromised patients. Am J Clin Pathol 120: 575-583, 2003
97. Alsaad KL, Tobar A, Belanger E, Ahmad M, Cattran DC, Herzenberg AM: Late-onset acute haemorrhagic necrotizing granulomatous adenovirus tubulointerstitial nephritis in a renal allograft. Nephrol Dial Transplant 22: 1257-1260, 2007
98. Cavdar C, Sayan M, Sifil A, Artuk C, Yilmaz N, Bahar H, Camsari T: The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis, and renal transplantation patients. Scand J Urol Nephrol 37: 71-76, 2003
99. Wyzgal J, Brydak LB, Zygier D, Paczek L, Powinski W, Grochowiecki T: Study on influenza vaccination in renal allograft recipients. Transplant Proc 34: 572-575, 2002
100. Sanchez-Fructuoso AI, Prats D, Naranjo P, Pernandez-Perez C, Gonzalez MJ, Mariano A, Gonzalez J, Figueredo MA, Martin JM, Paniagua V, Fereres J, Gomez de la Concha E, Barrientos A: Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: Mycophenolate versus azathioprine. Transplantation 69(3): 436-439, 2000
101. Ison MG: Adenovirus infections in transplant recipients. Clin Infect Dis 43: 331-339, 2006
102. Cushing MM, Brat DJ, Mosunjac ML Hennigar RA, Jernigan DB, Laniciotti R, Peterson LR, Goldsmith C, Rollin PE, Shieh WJ, Guarner J, Zaki SR: Fatal West Nile encephalitis in a renal transplant recipient. Am J Clin Pathol 121: 26-31, 2004
103. Wader H, Alangaden GJ, Sillix DH, El-Amm JM, Gruber SA, West MS, Granger DK, Garnick J, Chandresekar P, Miqdal SD, Haririan A: West Nile virus encephalitis: An emerging disease in renal transplant recipients. Clin Transplant 18: 753-758, 2004
104. Iwamoto M, Jernigan DB, Guasch A, Trepka MJ, Blackmore CG, Hellinger WC, Pham SM, Zaki S, Lanciotti RS, Lance-Parker SE, DiazGranados CA, Winquist AG, Perlino CA, Wiersma S, Hillyer KL, Goodman JL, Marfin AA, Chamberland ME, Petersen LR, West Nile Virus in Transplant Recipients Investigation Team: Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 348: 2196-2203, 2003
105. Kumar D, Prasad GVR, Zaltzman J, Levy GA, Humar A: Community-acquired west nile virus infection in solid-organ transplant recipients. Transplantation 77: 399-402, 2004